University of Switzerland Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2012
NCT01571908
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

University Hospitals of Lausanne, Switzerland

Active Ingredients

Drugs in Phase 2 Trials (3)

magnesium oxide (1 trial)

rocuronium (zemuron) (1 trial)

succinylcholine (anectine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 3